C Cumberland Pharmaceuticals Inc
C
Закрыт
5.46 13.04
Обзор
Изменение цены акций
24 ч
Мин.
4.71
Макс.
5.51
Доход | -1.9M -3.3M |
|---|---|
Продажи | -4.5M 9.1M |
Рентабельность продаж | -35.998 |
Сотрудники | 93 |
EBITDA | -1.9M -1.9M |
Следующий отчет о доходах | 4 авг. 2026 г. |
|---|
Рыночная капитализация | 719K 68M |
|---|---|
Предыдущая цена открытия | -7.58 |
Предыдущая цена закрытия | 5.46 |
Техническая оценка
By Trading Central
Уверенность
Very Strong Bearish Evidence
Cumberland Pharmaceuticals Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
Связанные новости
Сравнение c конкурентами
Изменение цены
Cumberland Pharmaceuticals Inc Прогноз
Финансовые показатели
Расходы на продажи и администрирование
Операционные расходы
Прибыль до уплаты налогов
Продажи
Себестоимость реализации
Валовая прибыль от продаж
Процентные расходы по долгу
EBITDA
Операционная прибыль
$
О компании Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
